stockrowJohnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) Operating cash flow
Johnson & Johnson's operating cash flow for fiscal 2025 was $24.5B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $26.2B. Over the past ten years it has ranged from $18.8B (fiscal 2016) to $24.5B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Johnson & Johnson ranks 2nd of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $24.5B | 1.09% |
| FY2024 | $24.3B | 6.47% |
| FY2023 | $22.8B | 7.54% |
| FY2022 | $21.2B | (9.47%) |
| FY2021 | $23.4B | (0.54%) |
| FY2020 | $23.5B | 0.51% |
| FY2019 | $23.4B | 5.47% |
| FY2018 | $22.2B | 5.44% |
| FY2017 | $21.1B | 12.20% |
| FY2016 | $18.8B | (4.10%) |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $7.7B | (10.40%) |
| Jun 2026 | $8.6B | 242.72% |
| Mar 2026 | $2.5B | (65.60%) |
| Dec 2025 | $7.3B | (20.29%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| LLY Eli Lilly and Company compare | $30.6B |
| JNJ Johnson & Johnson | $26.2B |
| ABBV AbbVie Inc. compare | $20.1B |
| MRK Merck & Co., Inc. compare | $20.0B |
| NVS Novartis AG compare | $17.3B |
| GILD Gilead Sciences, Inc. compare | $14.5B |
| PFE Pfizer Inc. compare | $14.2B |
| AZN AstraZeneca PLC compare | $13.2B |
| AMGN Amgen Inc. compare | $12.0B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement